{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   boosted with ritonavir   increases   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/atorvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1633\">atorvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   is predicted to   increase   the exposure to   atorvastatin .  Manufacturer advises adjust  atorvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   increases   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"combined hormonal contraceptives\" outputclass=\"int-drug\">Combined hormonal contraceptives</ph> <ph outputclass=\"int-substanceQualifier\">(containing ethinylestradiol)</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of increased ALT concentrations when given with</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Combined hormonal contraceptives   (containing ethinylestradiol)   are predicted to   increase   the risk of increased ALT concentrations when given with   voxilaprevir   with sofosbuvir and velpatasvir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Combined hormonal contraceptives</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">dabigatran</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   increases   the concentration of   dabigatran .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">Dabrafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabrafenib   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   is predicted to   increase   the exposure to   digoxin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">edoxaban</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   is predicted to   increase   the concentration of   edoxaban .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"esomeprazole\" outputclass=\"int-drug\">Esomeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose, see <xref format=\"dita\" href=\"drug/sofosbuvir-with-velpatasvir-and-voxilaprevir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP215871\">sofosbuvir with velpatasvir and voxilaprevir</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Esomeprazole   is predicted to   decrease   the exposure to   voxilaprevir .  Manufacturer advises adjust dose, see  sofosbuvir with velpatasvir and voxilaprevir .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esomeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvastatin\" outputclass=\"int-drug\">fluvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   is predicted to   increase   the exposure to   fluvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lansoprazole\" outputclass=\"int-drug\">Lansoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose, see <xref format=\"dita\" href=\"drug/sofosbuvir-with-velpatasvir-and-voxilaprevir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP215871\">sofosbuvir with velpatasvir and voxilaprevir</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lansoprazole   is predicted to   decrease   the exposure to   voxilaprevir .  Manufacturer advises adjust dose, see  sofosbuvir with velpatasvir and voxilaprevir .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lansoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   boosted with ritonavir   is predicted to   increase   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"modafinil\" outputclass=\"int-drug\">Modafinil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Modafinil   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Modafinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"omeprazole\" outputclass=\"int-drug\">Omeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose, see <xref format=\"dita\" href=\"drug/sofosbuvir-with-velpatasvir-and-voxilaprevir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP215871\">sofosbuvir with velpatasvir and voxilaprevir</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Omeprazole   is predicted to   decrease   the exposure to   voxilaprevir .  Manufacturer advises adjust dose, see  sofosbuvir with velpatasvir and voxilaprevir .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pantoprazole\" outputclass=\"int-drug\">Pantoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose, see <xref format=\"dita\" href=\"drug/sofosbuvir-with-velpatasvir-and-voxilaprevir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP215871\">sofosbuvir with velpatasvir and voxilaprevir</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pantoprazole   is predicted to   decrease   the exposure to   voxilaprevir .  Manufacturer advises adjust dose, see  sofosbuvir with velpatasvir and voxilaprevir .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pantoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pravastatin\" outputclass=\"int-drug\">pravastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust <ph otherprops=\"pravastatin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/pravastatin-sodium.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1642\">pravastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   moderately   increases   the exposure to   pravastatin .  Manufacturer advises monitor and adjust  pravastatin  dose .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pravastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rabeprazole\" outputclass=\"int-drug\">Rabeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose, see <xref format=\"dita\" href=\"drug/sofosbuvir-with-velpatasvir-and-voxilaprevir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP215871\">sofosbuvir with velpatasvir and voxilaprevir</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rabeprazole   is predicted to   decrease   the exposure to   voxilaprevir .  Manufacturer advises adjust dose, see  sofosbuvir with velpatasvir and voxilaprevir .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rabeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifabutin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   markedly   increases   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   is predicted to   increase   the exposure to   simvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   is predicted to   increase   the concentration of   sulfasalazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   potentially   increases   the concentration of   tenofovir disoproxil .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   boosted with ritonavir   is predicted to   increase   the concentration of   voxilaprevir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir#bnf_i1643858033626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-heading-drug\">Voxilaprevir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   is predicted to   increase   the concentration of   topotecan .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				}
			],
			"hasSearchLabel": " Voxilaprevir  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/voxilaprevir.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Voxilaprevir </title>"
			},
			"rdfs:label": "voxilaprevir"
		}
	]
}